## Review

**Reviewer:** aidlc-product-lead-agent
**Iteration:** 1

**Verdict:** READY

### Findings

| ID | Severity | Finding | Status |
|----|----------|---------|--------|
| R-01 | suggestion | US2.10 (Bangla-first render) would read better with a literal `L(bn, en)` example next to the AC so downstream Functional Design knows which helper signature to keep. | Carried — Functional Design concern, not a story-level defect. |
| R-02 | suggestion | Story IDs could include a hint of the bolt boundary (e.g. `[B1]` on the paste-parse + manual + repeat cluster). | Carried — Delivery Planning produces the bolt assignment, not the story IDs. |
| R-03 | suggestion | US3.7 (operate the test suite and coverage floor) is structural; one AC could carry a "what is measurable here" anchor (the CI badge for the 80 % floor). | Carried — README/CI-badge is a Construction-stage concern. |

### Notes

The advisory findings above are suggestions, not defects. Per the
advisory review contract, suggestions are gate input, not grounds
for NOT-READY. The story set is decision-ready for the human
gate.

### Coverage summary

- **Personas:** 3 + system actor (P-Owner, P-Staff, P-Viewer,
  P-System) — matches Q1 and the role × capability matrix.
- **Story count:** 39 stories across 3 epic families
  (Capture / Settle / Operate), all anchored to ≥ 1 FR ID and
  ≥ 1 NFR where the FR is money-touching.
- **Traceability:** every FR and NFR ID in `requirements.md` is
  declared in `traceability.json`'s `upstream_ids`. Every ID
  carries a coverage row with a `status` and a `target` (except
  NFR5.3 which is `Deferred` with `nfr-requirements` as the
  named downstream stage). No `GAP` rows.
- **Inline NFR pattern:** CC-AC cross-cutting list binds
  audit-immutability, role-gate, basis pill, status-bucket,
  i18n, tenant, coverage, TypeScript-strict, and comments-as-
  design at every relevant story.
- **Honest deferral:** US1.14.D, US1.15.D, US1.16.D, US3.9.D
  carry `[Deferred]` bodies with the Construction-stage
  resolution named (Q5=A: every FR cluster → story; phase-2
  differentiators defer the body).

Proceed to the human approval gate.

(End of review.)
